Amicus Therapeutics, Inc. (FOLD)
$14.49+0.00%Close
BUYBULL · day 98
Key stats
- Market cap
- $4.5B
- Beta
- 0.48
- P/E (TTM)
- -783.24
- 1W
- +0.21%
- 1M
- +0.42%
- vs SPY 1W
- +0.35%
- vs SPY 1M
- -2.09%
Industry peers
FMP comparable companies · ranked by market cap
- KNSABUYKiniksa Pharmaceuticals International, plc$6.0BBULLQ 23$78.53-0.90%
- CDTXCidara Therapeutics, Inc.$5.6B$221.38
- SRRKSELLScholar Rock Holding Corporation$4.9BCRISISQ 22$40.52-3.39%
- ADPTSELLAdaptive Biotechnologies Corporation$4.0BCRISISQ 6$25.28-1.13%
- CPRXBUYCatalyst Pharmaceuticals, Inc.$3.9BBULLQ 20$31.49+0.00%
- LEGNSELLLegend Biotech Corporation$3.3BRECOVERYQ 2$17.88+0.45%
- ARQTBUYArcutis Biotherapeutics, Inc.$3.3BRECOVERYQ 11$26.09-0.50%
- IDYASELLIDEAYA Biosciences, Inc.$3.3BBEARQ 25$34.26-4.99%
- TARSSELLTarsus Pharmaceuticals, Inc.$3.0BBEARQ 23$70.82-4.81%
- MLYSSELLMineralys Therapeutics, Inc.$1.9BCRISISQ 17$21.00-5.53%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 47
- VALUE
- 13
- GROWTH
- 43
- GARP
- 61
- TYPE
- Growth Compounder
Composite of Value · Growth · GARP
ROIC-1.4%
REV YoY-
ROE-2.3%
EPS YoY-
ROA-0.6%
GROSS87
OP8
NET-1
[VALUATION]
P/E TTM-783.24
P/E FWD25.62
SECTOR PE20.34
INDUSTRY PE13.84
P/B16.33
P/FCF-
EV/EBITDA82.29
EV/EBIT-
PEG0.68
FCF YIELD-
RISK
INT COV-
D/E176.24
ALTMAN Z-
CURR RATIO2.84
ND/EBITDA-
BETA0.48
Company news
FAQ
- What is LOPJLB’s current signal on FOLD?
- LOPJLB’s latest quantitative signal on Amicus Therapeutics, Inc. (FOLD) is BUY in a BULL regime. Signals are updated daily.
- What market regime is FOLD in?
- Amicus Therapeutics, Inc. (FOLD) is currently classified in the BULL HMM market regime on LOPJLB.
- What does Amicus Therapeutics, Inc. (FOLD) do?
- Amicus Therapeutics, Inc. is a biotechnology firm dedicated to the discovery, development, and delivery of medical treatments for rare conditions. Its primary commercial offering is Galafold, an orally administered precision medicine designed for adult patients with a confirmed diagnosis of Fabry disease, specifically those exhibiting an amenable galactosidase alpha gene variant as identified b…